PMID-20952020 – Degarelix Cardiovascular Safety Phase III
Smith MR, Klotz L, Persson BE, Olesen TK, Wilde AAM. Cardiovascular safety of degarelix: results from a 12-month, comparative, randomized, open label, parallel group phase III trial in patients with prostate cancer. J Urol. 2010;184(6):2313-2319.
Quick Reference
| Property | Value |
|---|---|
| PMID | 20952020 |
| DOI | 10.1016/j.juro.2010.08.012 |
| Year | 2010 |
| Journal | The Journal of Urology |
| Study Type | RCT (Phase III, CV safety analysis) |
| Evidence Level | II |
| Sample | 610 patients with prostate cancer |
| Peptide(s) Studied | Degarelix, Leuprolide |
Key Findings
- No meaningful QTc interval differences between degarelix and leuprolide groups
- Markedly abnormal QTc readings occurred in <1% of degarelix patients vs 1% of leuprolide patients
- Supraventricular arrhythmias: ~2% degarelix vs ~4% leuprolide
- Ischemic heart disease: 4% degarelix vs 10% leuprolide (notable numerical difference)
- Overall cardiovascular safety profiles were similar between treatments
- Cardiovascular events likely reflect the effects of testosterone suppression rather than direct drug effects
Study Design
Pre-specified cardiovascular safety analysis of the pivotal Phase III degarelix trial (CS21). ECG monitoring at baseline and throughout 12 months of treatment. Analysis of cardiac adverse events, QTc prolongation, and arrhythmias across treatment arms.
Limitations
- Study not powered specifically for cardiovascular endpoints
- Open-label design may introduce ascertainment bias
- Short follow-up (12 months) for cardiovascular outcomes
- Numerical differences in ischemic heart disease require confirmation in larger, dedicated CV safety trials
Clinical Relevance
While the overall conclusion was comparable cardiovascular safety, the numerical advantage of degarelix for ischemic heart disease (4% vs 10%) has generated significant interest, particularly for prostate cancer patients with pre-existing cardiovascular disease. This finding has been explored further in subsequent meta-analyses and has influenced treatment selection guidelines, especially for patients with cardiovascular comorbidities.
Related
#research #RCT #peptide #sexual-health #cardiovascular #evidence-level-II